Fungi | Jotup

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on:

Thursday, January 7, 2021

Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Psychedelic drug, Mushroom, Psychedelic therapy, Psilocybin therapy

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points:

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.

Further Research into Psilocybin Opens New Doors for Treatment

Retrieved on:

Thursday, January 7, 2021

Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Branches of biology, Psilocybin mushroom, Psilocybin, Psychedelic drug, Mushroom, Psychedelic therapy, Psilocybin therapy

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.

Key Points:

Also, in 2019, the FDA awarded the second Breakthrough Therapy designation to non-profit Usona Institute, which is studying the effects of psilocybin as an anti-depressant.
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
'Our focus of the study is exploring whether microdosing leads to changes in novelty perception or pattern recognition,' said Dr. Polito.
Dr. Polito is a Research Fellow in the Department of Cognitive Science at Macquarie University.

Mushroom Cultivation Industry - Global Market Outlook 2019-2027: Market is Expected to Reach $26.09 Billion - ResearchAndMarkets.com

Retrieved on:

Tuesday, January 5, 2021

Retail, Agriculture, Natural Resources, Food, Beverage, Edible fungi, Biology, Fungi, Organisms, Non-timber forest products, Biotechnology, Fungiculture, Microbiology, Sustainable agriculture, Mushroom, Cultivation

The "Mushroom Cultivation - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Mushroom Cultivation - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
Global Mushroom Cultivation market accounted for $16.37 billion in 2019 and is expected to reach $26.09 billion by 2027 growing at a CAGR of 6.0% during the forecast period.
Some of the factors such as the multi-functionality of mushrooms and cost-effectiveness connected with the cultivation of mushrooms are propelling the market growth.
In mushroom cultivation, waste products, which include straw, horse manure, gypsum, and wastewater, are used to cultivate high-quality mushrooms.

Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria

Retrieved on:

Wednesday, December 23, 2020

Fungi, Organisms, Branches of biology, Psychoactive fungi, Non-timber forest products, Amanita muscaria, Entheogens, Amanita, Mushroom, Dietary supplement

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Key Points:

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.
The Company's objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.
The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
This news release includes data that has been obtained from third party sources, including the findings from the Toxicology Assessment.

GRDG Sciences Announces New Food Preservative Vanexn Successfully Inhibits Candida albicans

Retrieved on:

Thursday, December 17, 2020

Yeasts, Gut flora, Pathogenic microbes, Branches of biology, Organisms, Fungi, Cándida, Aspergillus

WINTER HAVEN, Fla., Dec. 17, 2020 /PRNewswire/ --GRDG Sciences, LLC ("GRDG"), announced today that their new food preservative, Vanexn, successfully inhibits Aspergillus Niger, Talaromyces pinophilus, and Candida albicans.

Key Points:

WINTER HAVEN, Fla., Dec. 17, 2020 /PRNewswire/ --GRDG Sciences, LLC ("GRDG"), announced today that their new food preservative, Vanexn, successfully inhibits Aspergillus Niger, Talaromyces pinophilus, and Candida albicans.
Candida is the single most important cause of fungal infections worldwide according to the American Thoracic Society.
Vanexn was discovered by GRDG during previous research in the Florida Everglades and fills a need for new and more effective food preservatives.
To solve this "sleeper epidemic," GRDG is now working with global partners to further develop the process of integrating Vanexn into breads and baked goods.

Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing

Retrieved on:

Tuesday, December 15, 2020

Entheogens, Psychoactive fungi, Psychoactive drugs, Fungi, Organisms, Psilocybin mushroom, Psilocybin, Cannabis, Medical cannabis, Psilocybe semilanceata, Psilocybe, Legal status of psilocybin mushrooms

Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.

Key Points:

Way2Grow received approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements.
W2Gs research plans include the investigation of cannabis and psilocybin mushrooms growth plans and examination of their efficacy on treating unmet mental health conditions such as PTSD, addiction dependency, and anxiety.
W2Gs cultivation relies on a small, closed room approach to growing consistent organic medical cannabis and soon, medical grade psilocybin mushroom (Psilocybe semilanceata) production.
Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada).

REPEAT -- Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations

Retrieved on:

Thursday, November 26, 2020

Entheogens, Fungi, Psychoactive fungi, Psychoactive drugs, Branches of biology, Non-timber forest products, Psilocybin mushroom, Hallucinations, Mushroom, Psilocybin, Shrooms, Psychedelic drug

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.

Key Points:

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.
In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canadas leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.
Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy.
Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

Pure Extracts Advances Plans for the Processing of Functional Mushroom Formulations

Retrieved on:

Thursday, November 26, 2020

Entheogens, Fungi, Psychoactive fungi, Psychoactive drugs, Branches of biology, Non-timber forest products, Psilocybin mushroom, Hallucinations, Mushroom, Psilocybin, Shrooms, Psychedelic drug

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.

Key Points:

Pure Extracts has noted recent announcements showing increased institutional interest in the field of psychedelics in general and with a focus on promising mushroom varieties such as psilocybin specifically.
In that regard, Pure Extracts has signed a Letter of Intent (LOI) with one of Canadas leading functional mushroom wellness brands to co-develop CBD enhanced mushroom products.
Looking further ahead, Pure Extracts aims to eventually enter the growing field of psychedelic mushroom processing as an additional aspect of its diverse extraction market penetration strategy.
Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

Farmmi Further Expands International Sales

Retrieved on:

Monday, November 23, 2020

Fungi, Edible fungi, Food and drink, Lishui, Foods, Shiitake, Zhejiang, Mushroom, Edible mushroom

LISHUI, China, Nov. 23, 2020 /PRNewswire/ --Farmmi, Inc. ("Farmmi" or the "Company")(NASDAQ: FAMI), an agriculture products supplier in China, today announced a further expansion of its international sales.

Key Points:

LISHUI, China, Nov. 23, 2020 /PRNewswire/ --Farmmi, Inc. ("Farmmi" or the "Company")(NASDAQ: FAMI), an agriculture products supplier in China, today announced a further expansion of its international sales.
The Company's subsidiary, Zhejiang Forest Food Co., Ltd., has received another multi-product order for export to Israel.
Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products.
The Company's Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products.

Chaga Mushroom-Based Products Market to grow by $ 11.31 bn in 2020, Annanda Chaga Mushrooms and Baikal Herbs Ltd. emerge as Key Contributors to growth | Technavio

Retrieved on:

Friday, November 20, 2020

COVID-19 will have a high impact on the chaga mushroom-based products market.

Key Points:

COVID-19 will have a high impact on the chaga mushroom-based products market.
The market growth in 2020 is likely to increase compared to the market growth in 2019.
The launch of new chaga mushroom-based products is a major trend driving the growth of the market.
Chaga Mushroom-Based Products Market 2020-2024: Segmentation
Chaga Mushroom-Based Products Market is segmented as below: